Given Jazz Pharmaceuticals' history of stock price decline following an earnings miss, as seen in the previous quarter, it's likely that the reported earnings miss for Q4 could lead to a short-term negative impact on the stock price. The 3.0% miss in EPS expectations, despite an increase in revenue, suggests potential concerns over profitability and efficiency that could influence investor sentiment negatively.